Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $124,436.70 in Stock

Key Points

• Insider sale: Takeda insider Ramy Riad Ahmed Ibrahim sold 7,277 shares for $124,436.70, reducing his ownership by 6.62% to 102,588 shares. The sale covered tax-withholding obligations tied to vested equity awards.
• Stock performance and results: Takeda shares recently traded at $17.42, near the middle of their 52-week range, while the company reported quarterly revenue of $6.90 billion and EPS of $0.56.
• Investor sentiment: Institutional ownership stands at 9.17%, with several major funds increasing their positions. Analyst views remain mixed, resulting in a consensus “Hold” rating.

Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) insider Ramy Riad Ahmed Ibrahim sold 7,277 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $124,436.70. Following the transaction, the insider owned 102,588 shares in the company, valued at approximately $1,754,254.80. The trade was a 6.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Trading Down 0.3%

Shares of NYSE:TAK traded down $0.06 during trading on Wednesday, reaching $17.42. 2,004,364 shares of the company traded hands, compared to its average volume of 4,402,927. The firm has a market capitalization of $55.82 billion, a price-to-earnings ratio of 51.24 and a beta of -0.08. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $18.90. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The business's fifty day moving average is $16.49 and its 200-day moving average is $17.13.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The firm had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. As a group, analysts forecast that Takeda Pharmaceutical Co. will post 3.01 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership boosted its position in shares of Takeda Pharmaceutical by 100.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company's stock valued at $88,596,000 after purchasing an additional 2,854,069 shares in the last quarter. UBS Group AG boosted its holdings in shares of Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company's stock valued at $86,288,000 after buying an additional 1,869,323 shares in the last quarter. Qube Research & Technologies Ltd grew its position in shares of Takeda Pharmaceutical by 407.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company's stock worth $25,998,000 after buying an additional 1,426,184 shares during the period. Van ECK Associates Corp increased its stake in shares of Takeda Pharmaceutical by 98.4% in the 4th quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company's stock worth $35,941,000 after acquiring an additional 1,143,117 shares in the last quarter. Finally, Voloridge Investment Management LLC lifted its position in Takeda Pharmaceutical by 1,070.7% during the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company's stock valued at $15,005,000 after acquiring an additional 880,289 shares during the period. Hedge funds and other institutional investors own 9.17% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on TAK. Zacks Research raised Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 4th. Weiss Ratings cut shares of Takeda Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, July 30th. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Saturday, July 18th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Takeda Pharmaceutical presently has a consensus rating of "Hold".

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited NYSE: TAK is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source